Jodi Balderrama
Family Medicine · Sylva, NCNPI 1407490600
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 693 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 693 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- Lilly USA, LLC$862
- Otsuka America Pharmaceutical, Inc.$617
- Amgen$612
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$560
- plus $5K from 41 others
What the payments were for
- Food & beverage$11,618100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,631 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 92 | $121,462 |
| OzempicSemaglutide | 45 | $62,642 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $60,382 |
| JardianceEmpagliflozin | 51 | $51,800 |
| EliquisApixaban | 65 | $51,288 |
| RybelsusSemaglutide | 28 | $44,670 |
| Repatha SureclickEvolocumab | 42 | $43,155 |
| XareltoRivaroxaban | 25 | $33,130 |
| VraylarCariprazine Hcl | 13 | $21,144 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $20,589 |
| LinzessLinaclotide | 12 | $19,227 |
| VyvanseLisdexamfetamine Dimesylate | 30 | $11,056 |
| MyrbetriqMirabegron | 17 | $10,882 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $8,761 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $8,125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $862 | $121,46292 claims |
| Novo NordiskOzempic, Rybelsus | $1,469 | $107,31373 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $477 | $72,860102 claims |
| Boehringer IngelheimJardiance, Synjardy | $528 | $59,30064 claims |
| PfizerEliquis | $488 | $51,28865 claims |
| AbbVieVraylar, Linzess, Synthroid | $2,257 | $45,27971 claims |
| Johnson & JohnsonXarelto | $197 | $33,13025 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $270 | $16,32643 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $10,88217 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $189 | $8,76111 claims |
| MerckLagevrio (Eua) | $164 | $7,54114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Sylva
- William CromwellRaleigh$879K
- Steve VacalisGastonia$693K
- David DundeeWinston Salem$633K
- Kevin SodenCharlotte$558K
- Brian ForrestApex$398K
- Joseph KonenCharlotte$322K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- Domingo Rodriguez-CueGarner$253K
- Christopher ChaoCary$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.